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Abstract
Tobramycin nebuliser solution (TNS) has been investigated in several clinical trials, including a large, placebo-controlled study
that demonstrated efficacy over a 24-week period. The open-label extension phase of this trial enabled observations to be
conducted for an additional period of almost 18 months. Patients from both treatment arms (ns396) entered the open-label phase
and received up to nine 28-day on, 28-day off cycles of TNS 300 mg by aerosol twice daily (b.i.d.). Mean lung function in
patients who had received placebo during the double-blind phase improved during the first three cycles of the open-label
treatment. However, lung function in these patients did not recover to the levels seen in those patients who had received TNS
throughout the double-blind and open-label phases. In both groups of patients, improvement was maintained during the study.
Greater improvements were seen in adolescents compared with older patients. Adverse events were generally uncommon, with a
notably lower incidence of fever, anorexia, abdominal pain and vomiting than was observed in the double-blind phase among
patients who received placebo, and a generally low incidence of tinnitus. We conclude that long-term TNS administration is safe
and effective.
 2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Patients with cystic fibrosis (CF) have long been
recognized to succumb primarily to the gradual failure
of their lungs related to chronic and recurrent airway
infection, as well as gradual lung destruction. Patient
survival has improved over the past 30 years w1x, and
this is partly due to the development of new antibiotics.
However, infection with the most common airway path-
ogen, Pseudomonas aeruginosa, has been difficult to
treat on an outpatient basis, since most of the effective
drugs require intravenous administration. The adminis-
tration of antibiotics by inhalation is potentially more
effective and more convenient than intravenous admin-
istration w2x. Previously, tobramycin nebuliser solution
(TNS) has been prepared by reconstituting intravenous
tobramycin—a practice which is less than satisfactory
due to the inefficiency of delivery and the potential for
mucosal irritation. However, over the last 8 years a new
formulation of tobramycin has been specifically devel-
oped for administration by aerosol (TOBI ) (see Smith,
elsewhere in this supplement). This was tested in a 24-
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week, double-blind, randomized, placebo-controlled,
multi-center study w3x which found that TNS was well-
tolerated and was associated with improved pulmonary
function, decreased P. aeruginosa density in the sputum,
and decreased risk of hospitalization.
In addition to the 24-week, double-blind phase, the
protocol for this study allowed for an open-label exten-
sion for a period of almost 18 months. The extension
phase allowed further data to be collected on the long-
term use of TNS (in both patient groups from the
original study), as well as providing an opportunity to
study the effect of TNS administration in adolescent
patients. This paper presents the results of this extension
phase.
2. Methods
The initial, double-blind, randomized study recruited
520 patients at 69 centers over the course of approxi-
mately 1 year w3x. In order to be included in the study,
the patients had to have a documented diagnosis of CF,
moderate to severe lung impairment with FEV values1
of 25–75% predicted, and documented P. aeruginosa
infection. They needed to be at least 6 years of age and
relatively stable. Exclusion criteria included significant
haemoptysis, significant hypoxemia, hypersensitivity to
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Table 1
Patient characteristics at baselinea
Characteristic TNS Conventional careyplacebo
(ns258) (ns262)
Male, n (%) 149 (58%) 132 (50%)
Age mean"S.D. (years) 20.8"9.5 20.6"10.0
6–12 years, n (%) 55 (21%) 61 (23%)
13–17 years, n (%) 63 (24%) 67 (26%)
G18 years, n (%) 140 (54%) 134 (51%)
Use of dornase alfa, n (%) 198 (77%) 204 (78%)
FEV (no. tested)b1 257 262
Mean"S.D.—% of predicted 49.9"15.5 51.2"16.8
Adapted from table 1 in Doring et al. w2x.a ¨
FEV sforced expiratory volume in 1 s.b 1
aminoglycosides, recent pulmonary deterioration,
impaired renal function, or the presence of Burkholderia
cepacia in the airway in the last 2 years. Susceptibility
of P. aeruginosa organisms to tobramycin was not a
criterion. Informed consent was obtained from the
patients, parents or guardians, as appropriate for age.
On entry, patients were randomized into two groups—
conventional therapy, plus a placebo aerosol of quinine
(1.25 mg quinine sulfate in 5 ml, one-quarter normal
saline) by inhalation twice daily (the ‘placebo group’),
and conventional therapy plus TNS 300 mg in 5 ml
b.i.d. by aerosol (the ‘TNS group’).
Patients who completed the double-blind, 24-week
study were offered the opportunity to enter another 48-
week study in which they would receive open-label TNS
300 mg b.i.d. by aerosol. Patients who completed the
48-week open-label study were then offered the oppor-
tunity to participate in a second open-label study lasting
an additional 24 weeks.
The PARI LC PLUS jet nebulizer was used with a
PulmoAide compressor for both groups throughout the
entire study. The treatment aerosols were given twice
daily for 4 weeks and then a ‘drug vacation’ was given
for the following 4 weeks. Thus, patients who completed
the entire study received 12 8-week cycles, comprising
4 weeks of inhaled drug followed by 4 weeks off. They
either received TNS for all 12 cycles, or three cycles of
placebo followed by nine of TNS.
Patients received the best available care from their
physicians. They could be hospitalized and treated with
any antibiotic necessary, including intravenous (IV) but
excluding inhaled anti-pseudomonal antibiotics. Patients
who were receiving dornase alfa at entry to the study
could continue to receive it during the study, although
initiation of dornase alfa treatment during the study was
not allowed.
Spirometry was performed at each clinic visit. Patients
were monitored closely for improvements as well as the
appearance of adverse events. Pulmonary function, clin-
ical status, compliance with treatment, intercurrent ill-
nesses, medication use and occurrence of adverse events
were continually monitored throughout all three studies.
3. Results
Results are shown for the entire 2-year study period,
including the initial 24-week double-blind phase and
both subsequent open-label extension phases.
Table 1 indicates the demographics of the patients
recruited. Their mean FEV was approximately 50%1
predicted, suggesting that they would be likely to expe-
rience intermittent pulmonary deterioration and need
hospitalization. Approximately 70% of both patient
groups were receiving dornase alfa during the study.
Two hundred and fifty-eight patients were randomized
to receive TNS and 262 patients received a placebo.
The first open-label study began with 192 patients who
had previously received TNS and 204 patients who had
previously received a placebo. At the mid-point of the
first open-label study (after three cycles), 157 of the
original TNS patients and 155 of the initial placebo
therapy patients remained. The final three-cycle study
recruited 127 patients of the initial TNS recipients and
131 of the initial placebo patients.
Patients who received TNS showed improved FEV1
in the first 2 weeks (Fig. 1). Although there was some
variation in the degree of improvement, that improve-
ment persisted through the third cycle of the drug. At
the end of three cycles, the patients on TNS had a mean
change in FEV percentage predicted of 10.1%, com-1
pared with a change of y1.8% in the patients in the
placebo group.
At the start of the open-label study period, the patients
who had been receiving TNS continued to show mean
FEV values that, on average, remained above their1
baseline values. The patients who were crossed over
from placebo to open-label TNS had a marked improve-
ment in their pulmonary function. However, mean
FEV in the placebo group did not reach the levels seen1
in patients who had received with TNS in the initial,
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Fig. 1. Mean change in FEV % predicted during the course of the study in patients who received either TNS at all times (d) or placebo during1
the initial 24-week, double-blind phase and TNS for the remainder of the study (j). Solid lines represent periods on aerosol drug while dotted
lines represent periods off aerosols. nsTreatment effect (the change from baseline in the TNS less the change from baseline in the placebo
group).
double-blind phase. By the end of the 12th treatment
cycle, the mean FEV in the TNS-only group was 4.7%1
above the baseline value at the start of the study. Mean
FEV at endpoint in patients in the placebo-TNS cross-1
over group was slightly less than the baseline level, but
was still greater than it had been at the end of the
placebo phase (week 24).
In addition to improvement in the FEV , patients who1
were treated with TNS had a significant reduction in the
number of courses of IV anti-pseudomonal antibiotic
use per year. The 262 patients receiving conventional
therapy and placebo aerosols required 1.9 courses of
anti-pseudomonal antibiotics per patient per year, while
the 518 patients receiving TNS (both the randomized
and the open-label portions of the trial, regardless of
initial study group assignment) required approximately
1.25 courses per patient per year.
Because of the fragile pulmonary status that is typical
of teenagers, it was important to evaluate the effective-
ness of TNS in adolescents. For this reason, a subgroup
analysis was performed evaluating the change in FEV1
for patients aged 13–17 years. As shown in Fig. 2, the
adolescent patients treated with TNS from the beginning
had a marked improvement of approximately 15% in
their FEV over the first three cycles of treatment. This1
contrasts with an approximately 8% decline in FEV for1
the adolescent patients treated with placebo.
The patients who continued TNS maintained their
level of improvement over the next nine cycles, ending
with an FEV that was still an average of 14.3% above1
their week 0 baseline after 12 cycles of TNS (almost 2
years). The group of adolescent patients who crossed
over from the conventional therapy with placebo aerosol
to receive TNS in the open-label phase showed a marked
improvement during subsequent cycles. This degree of
improvement was similar to that seen in the group who
started on TNS in the double-blind study. Of importance,
the mean FEV values of this crossover group after nine1
cycles (72 weeks) of TNS were maintained at levels
above those at the start of the open-label part of the
study.
During the course of the study, numerous evaluations
for adverse events were performed. Fig. 3 shows the six
types of adverse events that occurred with significant
difference in frequency between the patients receiving
TNS (at any time, regardless of initial treatment group
assignment) and the patients receiving conventional
therapy with placebo aerosols during the first three drug
cycles.
Fever, anorexia, abdominal pain and vomiting all
occurred more commonly in patients receiving conven-
tional therapy with placebo aerosols than in those who
were receiving TNS. Voice alteration and tinnitus
occurred more frequently in patients who were receiving
TNS compared with those in the conventional therapyy
placebo aerosol portion of the study. The incidence of
voice alteration decreased as the duration of TNS use
increased. Ultimately, after using TNS for nearly 2 years,
the incidence of voice alteration was lower than it was
for the initial three cycles of patients receiving conven-
tional therapies with placebo aerosols. The incidence of
hearing loss in patients receiving conventional therapy
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Fig. 2. Mean change in FEV % predicted in adolescent patients (aged 13–17 years) who received either TNS at all times (d) or placebo during1
the initial 24-week, double-blind phase and TNS for the remainder of the study (j). Solid lines represent periods on aerosol drug while dotted
lines represent periods off aerosols).
Fig. 3. The incidence of adverse events in patients receiving TNS at any time (j) compared with the incidence of adverse events reported during
the double-blind phase by patients receiving placebo (h). Only those adverse events that occurred with significantly different (P-0.05) fre-
quencies between the two groups are shown.
with placebo aerosols was 1.1%, and it ranged from
-1% to a maximum of 1.4% in the various cycles of
patients receiving TNS. No events of hearing loss
appeared to be related to TNS use; they were instead
related to otitis media andyor the use of IV aminogly-
cosides. Audiograms showingG15 dB bilateral decrease
in hearing were observed in only two patients. Both
were judged by the investigators at the site to be
transient effects not attributed to TNS. Both patients
completed the 96-week study.
4. Discussion
This study shows that it is possible to maintain for at
least 2 years the benefits previously demonstrated by
Ramsey et al. w3x in the use of TNS for three 8-week
drug cycles (4 weeks on, 4 weeks off).
The patients treated in this study were typical of
patients in most CF clinics, with a mean age of approx-
imately 20 years and a mean FEV of approximately1
50% predicted. Patients initially treated with TNS con-
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tinued to have improved pulmonary function 92 weeks
after the start of the study compared to their values at
week 0. When patients crossed over to TNS after the
initial 24 weeks on conventional therapy with placebo
aerosols, they showed an improvement that was similar
to that of the patients who started on TNS on day 0. It
is thus clear that patients with moderately-severe CF
lung disease experience improved lung function as a
result of the inhalation of TNS on an alternate month
format.
The benefits that accrued to the subgroup of adoles-
cent patients receiving TNS were nearly twice the
benefits shown in the TNS group as a whole. This is
particularly striking in comparison with the conventional
therapy plus placebo group, in which the adolescent
subgroup showed a more rapid rate of decline than that
of the group as a whole. The group of teenage patients
receiving TNS had improved pulmonary function (an
average of 14.3% above baseline) 92 weeks after starting
the treatment.
Patients in the TNS group had a lesser requirement
for intravenous antibiotics to treat pseudomonal infec-
tions. Patients receiving TNS, whether in the randomized
portion or the open-label portion of the study, needed
only approximately two-thirds the number of IV antibi-
otic courses to treat P. aeruginosa infection compared
with patients who received conventional therapy and
placebo.
The safety data reported suggest that TNS was gen-
erally well-tolerated by the patients who received it. The
fact that four types of adverse events (fever, anorexia,
abdominal pain and vomiting) were more common in
patients receiving conventional therapy and placebo
aerosols than in patients receiving TNS suggests that
TNS may actually improve overall patient comfort and
metabolism. The problems of voice alteration and tin-
nitus, which occurred more commonly in patients on
TNS, were relatively mild and transient.
In conclusion, this three-phase study of patients treat-
ed with TNS aerosols every other month for as long as
96 weeks showed that TNS is an effective and safe
mode of therapy for patients with CF. The improvement
shown in patients who took TNS after initially receiving
conventional therapy with placebo aerosols demonstrates
that the benefits of TNS, shown by Ramsey et al. w3x,
could be maintained for nearly 2 years, and that these
benefits were not limited to the group of 258 patients
initially treated with TNS. Furthermore, the open-label
studies clearly demonstrate the remarkable benefit TNS
holds for adolescent patients. These studies also provide
stronger evidence that TNS causes few side-effects and
may actually lessen the incidence of various systemic
complaints. Further studies are needed to document the
long-term effects of TNS on the typical gradual deteri-
oration in lung function, on improvement in patient
quality of life and on patient safety.
References
w1x Frederiksen , Lanng S, Koch C, et al. Improved survival in the
Danish center-treated cystic fibrosis patients: result of aggres-
sive treatment. Pediatr Pulmonol 1996;21(3):153–8.
w2x Doring G, Conway SP, Heijerman HGM, et al. Antibiotic¨
therapy against Pseudomonas aeruginosa in cystic fibrosis: a
European consensus. Eur Resp J 2000;16:749–67.
w3x Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of
aerosolized tobramycin in patients with cystic fibrosis. N Engl
J Med 1993;328:1740–6.
